Enanta Pharmaceuticals, Inc
ENTAEnanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule drugs primarily for the treatment of viral infections and liver diseases. Founded in 1994 and headquartered in Watertown, Massachusetts, Enanta specializes in liver health, particularly hepatitis B and C, as well as other viral illnesses. The company's research and development efforts aim to create novel therapies to address unmet medical needs in these areas.
Company News
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Enanta Pharmaceuticals released positive Phase 2b trial results for zelicapavir, an oral RSV treatment that demonstrated clinically meaningful symptom reduction in high-risk adult patients, particularly those with chronic conditions.
Multiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.
Multiple healthcare stocks experienced significant price movements during Friday's after-market trading session, with some companies seeing notable gains while others experienced declines.
The FDA has approved a label expansion for AbbVie's Mavyret to include the treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis. Mavyret has shown a 96% cure rate in an 8-week treatment with mostly mild side effects.
